Menu Close

Asteroid Study

  • Posted on Feb 13, 2018

Mereo BioPharma is sponsoring a multi-centre international clinical trial to study the effects of anti-sclerostin therapy drug Setrusumab (previously called BPS804) on bone in OI. The study has now started recruiting patients in the UK, and at multiple sites across Europe, the United States, and Canada. Adults between 18 and 75 years old who have a diagnosis of OI Types I, III, or IV may be eligible for this 1-year clinical research study, which aims to enrol up to 140 patients.

Visit the Clinical Trials website or the Asteroid Study website to learn more, find your nearest study location, and register your interest in participation. If you have any additional questions, please email the Asteroid Study team. Their study contacts will be able to tell you more about the clinical research study, review eligibility criteria, and find a site near you.

Please see this short film about the study

Get involved Categories